Transparent, Evidence-Based, and Consultative: Reframing Pakistan’s Drug Pricing Policy
ISLAMABAD — In a critical move to balance healthcare affordability with the economic viability of the pharmaceutical sector, Finance Minister Muhammad Aurangzeb emphasized that all decisions regarding drug pricing in Pakistan must be transparent, evidence-based, and grounded in a consultative approach.
Speaking at the eighth meeting of the Cabinet Committee constituted by the Prime Minister to review recommendations from the Drug Pricing Committee (DPC) and the Policy Board of the Drug Regulatory Authority of Pakistan (DRAP), the Finance Minister underscored that public interest must remain the guiding principle behind healthcare regulation.
The meeting, held in Islamabad, brought together key policymakers and health officials to evaluate a wide spectrum of issues. These included new price fixation cases, hardship applications submitted by pharmaceutical manufacturers, overall pricing policy mechanisms, and broader strategies to ensure the uninterrupted market availability of essential life-saving medicines.
During the session, DRAP representatives delivered a comprehensive presentation detailing recent regulatory developments, progress made since the previous committee session, and fresh proposals submitted for executive consideration.
Balancing Patient Access with Supply Chain Sustainability
At the core of the Finance Minister’s address lies a complex, decades-long challenge within Pakistan’s healthcare system: ensuring that essential medicines remain affordable for ordinary citizens without squeezing pharmaceutical manufacturers to the point of product withdrawal or market severe shortages.
“Drug pricing decisions should be transparent, evidence-based with a consultative approach, and guided by the broader public interest,” Minister Aurangzeb stated. He emphasized the critical necessity of striking a sustainable balance between patient access to essential treatments and the economic reality faced by drug manufacturers.
In recent years, Pakistan’s pharmaceutical industry has faced sharp cost pressures. A major factor is currency depreciation, which inflates the cost of Active Pharmaceutical Ingredients (APIs) and raw materials imported from abroad. Coupled with rising energy tariffs and logistics costs, local manufacturing expenses have surged.
When regulatory price caps fail to adjust to these underlying economic realities, manufacturers often halt the production of lower-margin, critical drugs. This frequently creates artificial or localized shortages, leaving vulnerable patients reliant on expensive imported alternatives or precarious black markets.
Conversely, unmonitored price increases place a heavy financial burden on Pakistani households. With out-of-pocket healthcare expenses accounting for 70–75% of total private health spending in the country—and medicines taking up the majority of that share—uncontrolled price hikes directly threaten household budgets and force families into medical impoverishment.
Key Pillars of the Strategy
To mitigate these twin risks, the Cabinet Committee outlined a framework built on three key principles designed to modernize Pakistan’s pharmaceutical landscape:
Evidence-Based Price Adjustments: Price modifications—whether for new drug formulations or hardship applications—must be justified through clear data, cost audit trails, and global benchmark comparisons rather than ad-hoc requests.
Consultative Stakeholder Engagement: Regulators, industry representatives, healthcare providers, and public health experts will maintain an ongoing dialogue to resolve supply chain friction before it triggers national medicine shortages.
Public Engagement & Rationale: The government plans to clearly communicate the reasoning behind price changes to the public, fostering trust and transparency around sensitive regulatory moves.
Addressing Shortages and Building Trust
Past delays in price reviews and unpredictable regulatory pathways have routinely disrupted the supply chains of critical therapies. By enforcing predictable operational mechanisms within DRAP, the Cabinet Committee aims to streamline approval pipelines and prevent market bottlenecks.
